phytomenadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2843	84-80-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vitamin K1 phytomenadione vitamin K phytonadione phytylmenadione phytylmenaquinone phylloquinone	A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K. Molecular weight: 450.71 Formula: C31H46O2 CLOGP: 11.69 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 34.14 ALOGS: -6.88 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vitamin K1
phytomenadione
vitamin K
phytonadione
phytylmenadione
phytylmenaquinone
phylloquinone

A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Molecular weight: 450.71
Formula: C31H46O2
CLOGP: 11.69
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 34.14
ALOGS: -6.88
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O
20	mg	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.32 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 18, 2000	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis	204.48	13.92	69	9588	8748	63470617
International normalised ratio increased	79.91	13.92	62	9595	46363	63433002
Coagulopathy	62.63	13.92	39	9618	20505	63458860
Multiple organ dysfunction syndrome	55.59	13.92	55	9602	56697	63422668
Cystic fibrosis	54.25	13.92	20	9637	3276	63476089
Sepsis	51.16	13.92	87	9570	153036	63326329
Renal vascular thrombosis	47.06	13.92	8	9649	46	63479319
Ascites	46.58	13.92	43	9614	40685	63438680
Cholestasis	39.45	13.92	34	9623	29400	63449965
Factor V inhibition	37.63	13.92	8	9649	168	63479197
Injury associated with device	34.95	13.92	15	9642	3651	63475714
Thrombocytopenia	33.31	13.92	72	9585	151085	63328280
Osteochondritis	30.35	13.92	5	9652	23	63479342
Hepatic failure	28.50	13.92	31	9626	35625	63443740
Haematemesis	27.07	13.92	28	9629	30384	63448981
Drug intolerance	26.71	13.92	7	9650	308654	63170711
Intestinal dilatation	26.69	13.92	10	9647	1712	63477653
Pancreatitis chronic	26.47	13.92	11	9646	2473	63476892
Haemorrhage neonatal	26.14	13.92	5	9652	60	63479305
Superior sagittal sinus thrombosis	25.70	13.92	8	9649	783	63478582
Arthropathy	25.34	13.92	3	9654	234789	63244576
Respiratory failure	24.14	13.92	50	9607	101808	63377557
Transverse sinus thrombosis	23.98	13.92	7	9650	551	63478814
Premature baby	23.91	13.92	22	9635	20713	63458652
Acute kidney injury	23.85	13.92	91	9566	263324	63216041
Prothrombin time prolonged	23.83	13.92	16	9641	9548	63469817
Suspected transmission of an infectious agent via product	23.28	13.92	6	9651	296	63479069
Haemoptysis	23.00	13.92	25	9632	28701	63450664
Contraindicated product administered	22.95	13.92	3	9654	217645	63261720
Epidermolysis	22.62	13.92	7	9650	672	63478693
Acute hepatic failure	22.21	13.92	20	9637	18307	63461058
Rheumatoid arthritis	21.49	13.92	6	9651	253813	63225552
Vitamin K deficiency	21.04	13.92	6	9651	434	63478931
Activated partial thromboplastin time prolonged	20.79	13.92	13	9644	6880	63472485
Haemorrhage	20.77	13.92	35	9622	60987	63418378
Neonatal anuria	20.76	13.92	4	9653	50	63479315
Stevens-Johnson syndrome	20.47	13.92	22	9635	24928	63454437
Necrotising enterocolitis neonatal	20.18	13.92	5	9652	210	63479155
Cytokine release syndrome	20.13	13.92	17	9640	14297	63465068
Hypokalaemia	20.11	13.92	47	9610	103757	63375608
Acute respiratory distress syndrome	19.75	13.92	21	9636	23513	63455852
Therapeutic product effect decreased	19.58	13.92	3	9654	193184	63286181
Blood bilirubin increased	19.36	13.92	26	9631	37114	63442251
Blood alkaline phosphatase increased	19.30	13.92	28	9629	42939	63436426
Hepatic encephalopathy	19.25	13.92	15	9642	11267	63468098
Bilirubin conjugated increased	18.78	13.92	9	9648	2825	63476540
Retroperitoneal haematoma	18.55	13.92	9	9648	2904	63476461
Toxic epidermal necrolysis	18.48	13.92	21	9636	25313	63454052
Pain	18.39	13.92	55	9602	740573	62738792
Terminal ileitis	17.92	13.92	6	9651	740	63478625
HER2 positive breast cancer	17.41	13.92	5	9652	371	63478994
Pelvic fluid collection	16.98	13.92	6	9651	870	63478495
Oligohydramnios	16.71	13.92	11	9646	6355	63473010
Aspartate aminotransferase increased	16.54	13.92	40	9617	90237	63389128
Gamma-glutamyltransferase increased	16.50	13.92	23	9634	34008	63445357
Disseminated intravascular coagulation	15.99	13.92	17	9640	19034	63460331
Pulmonary function test decreased	15.97	13.92	9	9648	3938	63475427
Pleural effusion	15.70	13.92	40	9617	93170	63386195
Clostridium difficile infection	15.68	13.92	21	9636	29901	63449464
Hepatocellular injury	15.56	13.92	20	9637	27361	63452004
Wound	15.52	13.92	3	9654	163260	63316105
Renal failure	15.37	13.92	46	9611	117606	63361759
Drug reaction with eosinophilia and systemic symptoms	15.12	13.92	22	9635	33814	63445551
Jugular vein thrombosis	15.08	13.92	8	9649	3110	63476255
Hyperbilirubinaemia	15.02	13.92	13	9644	11301	63468064
Foetal growth restriction	15.00	13.92	11	9646	7542	63471823
Septic shock	14.95	13.92	32	9625	66597	63412768
Epicondylitis	14.62	13.92	7	9650	2193	63477172
Foetal exposure during pregnancy	14.60	13.92	21	9636	31941	63447424
Treatment failure	14.60	13.92	6	9651	199037	63280328
Hepatosplenic candidiasis	14.34	13.92	4	9653	267	63479098
Pulmonary pain	14.24	13.92	8	9649	3482	63475883
Subdural haematoma	14.23	13.92	14	9643	14314	63465051
Discomfort	14.08	13.92	4	9653	167370	63311995

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	425.87	14.92	149	12984	8452	34935346
Appendicitis	373.84	14.92	157	12976	14650	34929148
Ascites	308.49	14.92	201	12932	46370	34897428
Cardiogenic shock	291.69	14.92	159	12974	26459	34917339
Stress	253.86	14.92	152	12981	30195	34913603
Multiple organ dysfunction syndrome	235.49	14.92	209	12924	76357	34867441
Abdominal distension	219.37	14.92	179	12954	58313	34885485
Ventricular fibrillation	194.56	14.92	116	13017	22838	34920960
Blood phosphorus increased	185.18	14.92	79	13054	7642	34936156
Infective pulmonary exacerbation of cystic fibrosis	177.83	14.92	74	13059	6727	34937071
Hyponatraemia	152.46	14.92	171	12962	82520	34861278
Sepsis	129.12	14.92	227	12906	166334	34777464
Abdominal pain	125.54	14.92	222	12911	163396	34780402
General physical health deterioration	98.20	14.92	174	12959	128095	34815703
Constipation	96.22	14.92	179	12954	136803	34806995
Myasthenia gravis	80.19	14.92	43	13090	6897	34936901
Dry mouth	80.12	14.92	76	13057	30089	34913709
Blood uric acid increased	74.68	14.92	46	13087	9578	34934220
Vomiting	69.21	14.92	227	12906	247394	34696404
Toxic epidermal necrolysis	58.35	14.92	55	13078	21591	34922207
International normalised ratio increased	53.77	14.92	77	13056	47250	34896548
Blood cholesterol increased	51.21	14.92	50	13083	20493	34923305
Drug therapy	49.72	14.92	18	13115	1123	34942675
Hyperphosphataemia	47.11	14.92	26	13107	4411	34939387
Cystic fibrosis	43.18	14.92	18	13115	1640	34942158
Analgesic therapy	40.72	14.92	15	13118	983	34942815
Sleep disorder therapy	40.36	14.92	15	13118	1008	34942790
Hyper IgE syndrome	38.61	14.92	8	13125	55	34943743
Hypophosphataemia	37.60	14.92	32	13101	10994	34932804
Incorrect route of product administration	36.75	14.92	36	13097	14809	34928989
Hepatic failure	36.05	14.92	54	13079	34477	34909321
Toxicity to various agents	33.11	14.92	17	13116	200345	34743453
Iron deficiency	32.55	14.92	22	13111	5359	34938439
Nausea	31.67	14.92	227	12906	339681	34604117
Dizziness	24.09	14.92	28	13105	218493	34725305
Myocardial infarction	23.64	14.92	8	13125	121077	34822721
Somnolence	23.34	14.92	93	13040	111023	34832775
Hyperbilirubinaemia	23.04	14.92	30	13103	16813	34926985
Bacterial infection	22.73	14.92	30	13103	17033	34926765
Fatigue	22.71	14.92	68	13065	370585	34573213
Drug ineffective	22.49	14.92	92	13041	456659	34487139
Hepatic encephalopathy	21.41	14.92	27	13106	14658	34929140
Activated partial thromboplastin time prolonged	21.36	14.92	21	13112	8674	34935124
Hyphaema	20.95	14.92	8	13125	579	34943219
Cystic fibrosis related diabetes	20.79	14.92	6	13127	180	34943618
Coagulopathy	20.72	14.92	31	13102	19758	34924040
Epileptic encephalopathy	20.13	14.92	6	13127	202	34943596
Neuralgia	19.25	14.92	26	13107	15087	34928711
Acute hepatic failure	19.14	14.92	25	13108	14049	34929749
Cortical visual impairment	18.66	14.92	4	13129	33	34943765
Pain	17.81	14.92	31	13102	204644	34739154
Coagulation time prolonged	17.70	14.92	9	13124	1293	34942505
Bronchopulmonary aspergillosis allergic	17.41	14.92	8	13125	921	34942877
Dysmorphism	16.97	14.92	12	13121	3144	34940654
Iatrogenic infection	16.30	14.92	4	13129	63	34943735
Restrictive cardiomyopathy	16.09	14.92	7	13126	708	34943090
Sputum discoloured	15.80	14.92	17	13116	7795	34936003
Fall	15.67	14.92	33	13100	202852	34740946
Regurgitation	15.46	14.92	9	13124	1690	34942108
Condition aggravated	15.36	14.92	124	13009	192072	34751726
Skin candida	15.16	14.92	6	13127	478	34943320
Peripheral swelling	15.03	14.92	5	13128	76536	34867262

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	479.15	13.38	148	20155	8403	79715682
Appendicitis	374.25	13.38	155	20148	20639	79703446
Ascites	363.50	13.38	231	20072	75331	79648754
Infective pulmonary exacerbation of cystic fibrosis	337.66	13.38	126	20177	12725	79711360
Multiple organ dysfunction syndrome	304.69	13.38	249	20054	119997	79604088
Cardiogenic shock	300.84	13.38	166	20137	41748	79682337
Ventricular fibrillation	206.11	13.38	118	20185	31808	79692277
Abdominal distension	203.76	13.38	198	20105	119452	79604633
Sepsis	199.34	13.38	291	20012	269137	79454948
Blood phosphorus increased	192.44	13.38	79	20224	10268	79713817
Stress	185.13	13.38	157	20146	79455	79644630
Hyponatraemia	119.74	13.38	184	20119	177664	79546421
International normalised ratio increased	116.46	13.38	125	20178	84596	79639489
Constipation	86.07	13.38	209	20094	282841	79441244
Abdominal pain	84.63	13.38	254	20049	389315	79334770
Myasthenia gravis	79.55	13.38	43	20260	10356	79713729
Blood uric acid increased	77.25	13.38	46	20257	13314	79710771
General physical health deterioration	76.06	13.38	196	20107	275042	79449043
Toxic epidermal necrolysis	74.31	13.38	73	20230	44508	79679577
Cystic fibrosis	73.41	13.38	30	20273	3850	79720235
Coagulopathy	69.61	13.38	64	20239	35942	79688143
Hyperphosphataemia	62.08	13.38	31	20272	6345	79717740
Hepatic failure	58.51	13.38	75	20228	61137	79662948
Drug therapy	55.67	13.38	18	20285	1183	79722902
Analgesic therapy	46.27	13.38	15	20288	994	79723091
Sleep disorder therapy	46.05	13.38	15	20288	1009	79723076
Factor V inhibition	45.92	13.38	12	20291	369	79723716
Pain	41.83	13.38	72	20231	703730	79020355
Dry mouth	41.77	13.38	78	20225	87941	79636144
Hypophosphataemia	39.66	13.38	36	20267	19877	79704208
Hepatic encephalopathy	39.20	13.38	39	20264	24127	79699958
Activated partial thromboplastin time prolonged	39.19	13.38	31	20272	14197	79709888
Vomiting	38.91	13.38	296	20007	665532	79058553
Hyperbilirubinaemia	38.73	13.38	39	20264	24479	79699606
Respiratory failure	38.26	13.38	117	20186	180794	79543291
Haemoptysis	37.69	13.38	58	20245	55941	79668144
Toxicity to various agents	34.38	13.38	34	20269	421506	79302579
Renal vascular thrombosis	34.17	13.38	7	20296	70	79724015
Arthropathy	34.01	13.38	3	20300	177108	79546977
Thrombocytopenia	31.20	13.38	142	20161	265117	79458968
Dizziness	31.10	13.38	54	20249	526387	79197698
Prothrombin time prolonged	30.65	13.38	29	20274	16870	79707215
Acute hepatic failure	30.52	13.38	38	20265	30075	79694010
Cytokine release syndrome	29.62	13.38	41	20262	35957	79688128
Cholestasis	28.32	13.38	49	20254	52060	79672025
Blood bilirubin increased	28.11	13.38	56	20247	66176	79657909
Fall	27.03	13.38	52	20251	487577	79236508
Iron deficiency	26.77	13.38	22	20281	10632	79713453
Osteochondritis	26.38	13.38	5	20298	32	79724053
Joint swelling	25.02	13.38	22	20281	288624	79435461
Incorrect route of product administration	24.66	13.38	37	20266	34892	79689193
Hyper IgE syndrome	24.21	13.38	8	20295	563	79723522
Product use issue	23.54	13.38	12	20291	209810	79514275
Bacterial infection	23.33	13.38	34	20269	31246	79692839
Subdural haematoma	23.20	13.38	34	20269	31400	79692685
Transverse sinus thrombosis	23.02	13.38	8	20295	657	79723428
Contraindicated product administered	22.74	13.38	6	20297	157532	79566553
Therapeutic product effect decreased	22.25	13.38	7	20296	163856	79560229
Cystic fibrosis related diabetes	21.94	13.38	6	20297	220	79723865
Disseminated intravascular coagulation	21.19	13.38	35	20268	35807	79688278
Cortical visual impairment	21.05	13.38	4	20299	26	79724059
Coagulation time prolonged	21.01	13.38	11	20292	2484	79721601
Arthralgia	20.96	13.38	75	20228	571728	79152357
Drug ineffective	20.77	13.38	176	20127	1080737	78643348
Hyphaema	20.62	13.38	8	20295	896	79723189
Transaminases increased	19.89	13.38	42	20261	51701	79672384
Restrictive cardiomyopathy	19.77	13.38	8	20295	1000	79723085
Pulmonary function test decreased	19.67	13.38	16	20287	7621	79716464
Neutropenic colitis	19.17	13.38	14	20289	5693	79718392
Acute kidney injury	18.59	13.38	208	20095	519196	79204889
Septic shock	18.54	13.38	71	20232	122730	79601355
Hypersensitivity	18.26	13.38	24	20279	262215	79461870
Distal intestinal obstruction syndrome	18.08	13.38	7	20296	780	79723305
Drug reaction with eosinophilia and systemic symptoms	17.94	13.38	46	20257	64198	79659887
Jaundice	17.90	13.38	41	20262	53308	79670777
Gait disturbance	17.75	13.38	16	20287	207490	79516595
Discomfort	17.72	13.38	5	20298	125612	79598473
Intestinal dilatation	17.46	13.38	10	20293	2690	79721395
Escherichia bacteraemia	17.44	13.38	14	20289	6548	79717537
Abdominal discomfort	17.40	13.38	23	20280	250704	79473381
Treatment failure	17.33	13.38	11	20292	170475	79553610
Arthritis	17.31	13.38	4	20299	114876	79609209
Iatrogenic infection	17.29	13.38	4	20299	73	79724012
Epileptic encephalopathy	17.29	13.38	6	20297	490	79723595
Sputum increased	17.07	13.38	12	20291	4601	79719484
Pericarditis	17.01	13.38	3	20300	104233	79619852
Nasopharyngitis	16.90	13.38	24	20279	253857	79470228
Epidermolysis	16.67	13.38	7	20296	961	79723124
Somnolence	16.64	13.38	111	20192	238870	79485215
Intentional product use issue	16.62	13.38	9	20294	152103	79571982
Febrile neutropenia	16.51	13.38	108	20195	230891	79493194
Haematemesis	16.26	13.38	39	20264	52225	79671860
Pancreatitis chronic	16.15	13.38	11	20292	4008	79720077
Superior sagittal sinus thrombosis	16.04	13.38	7	20296	1056	79723029
Myocardial infarction	15.99	13.38	14	20289	184115	79539970
Peripheral swelling	15.58	13.38	28	20275	269589	79454496
Fatigue	15.41	13.38	157	20146	929570	78794515
HER2 positive breast cancer	15.40	13.38	5	20298	333	79723752
Anaemia	15.36	13.38	177	20126	444838	79279247
Mobility decreased	15.25	13.38	6	20297	122169	79601916
Vitamin K deficiency	15.05	13.38	6	20297	722	79723363
Systemic lupus erythematosus	15.04	13.38	6	20297	121143	79602942
Tumour lysis syndrome	15.00	13.38	24	20279	23915	79700170
Jugular vein thrombosis	14.95	13.38	11	20292	4527	79719558
Regurgitation	14.57	13.38	9	20294	2778	79721307
Lactobacillus test positive	14.30	13.38	3	20300	34	79724051
Haemorrhage	14.01	13.38	53	20250	91065	79633020
Blood cholesterol increased	13.97	13.38	50	20253	83670	79640415
Back pain	13.91	13.38	36	20267	304144	79419941
Acute respiratory distress syndrome	13.83	13.38	33	20270	44034	79680051
Heart transplant	13.83	13.38	7	20296	1474	79722611
Bronchopulmonary aspergillosis allergic	13.80	13.38	9	20294	3052	79721033
Medical device site haemorrhage	13.77	13.38	4	20299	183	79723902
Pruritus	13.63	13.38	53	20250	394595	79329490

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BA01	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Vitamin K
FDA CS	M0022806	Vitamin K
MeSH PA	D000933	Antifibrinolytic Agents
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D018977	Micronutrients
MeSH PA	D014815	Vitamins
FDA PE	N0000175965	Increased Prothrombin Activity
FDA EPC	N0000175966	Warfarin Reversal Agent
FDA PE	N0000175982	Reversed Anticoagulation Activity
FDA EPC	N0000180191	Vitamin K
CHEBI has role	CHEBI:23357	cofactor
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:24020	fat-soluble vitamins
CHEBI has role	CHEBI:75771	Mus musculus metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Osteoporosis	indication	64859006	DOID:11476
Factor II deficiency	indication	73975000
Postmenopausal osteoporosis	indication	102447009
Prevention of Neonatal Hemorrhagic Disease	indication
Antibiotic-Induced Hypoprothrombinemia	indication
Neonatal Hemorrhagic Disease	indication
Vitamin K Deficiency Induced Hypoprothrombinemia	indication
Anticoagulant-Induced Prothrombin Deficiency	indication
Obstruction of bile duct	off-label use	30144000
Abetalipoproteinemia	off-label use	190787008	DOID:1386
Constipation	contraindication	14760008	DOID:2089
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Vitamin E deficiency	contraindication	54137008
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Anemia due to enzyme deficiency	contraindication	111577008
Neoplasm of endometrium	contraindication	123844007	DOID:1380
Neoplasm of prostate	contraindication	126906006	DOID:10283
Osteolysis	contraindication	203522001
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Malignant tumor of cervix	contraindication	363354003	DOID:4362
Central nervous system depression	contraindication	418072004
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Alpha-synuclein	Transporter	P37840	SYUA_HUMAN		IC50	4.82		CHEMBL

External reference:

ID	Source
4017772	VUID
N0000146136	NUI
D00148	KEGG_DRUG
4017772	VANDF
4018981	VANDF
4021719	VANDF
4021911	VANDF
C0031862	UMLSCUI
CHEBI:18067	CHEBI
PQN	PDB_CHEM_ID
CHEMBL1550	ChEMBL_ID
CHEMBL1201519	ChEMBL_ID
DB01022	DRUGBANK_ID
5284607	PUBCHEM_CID
11258	RXNORM
1433	MMSL
15677	MMSL
199215	MMSL
42273	MMSL
5298	MMSL
d03135	MMSL
001038	NDDF
001042	NDDF
63136007	SNOMEDCT_US
65183007	SNOMEDCT_US
66656000	SNOMEDCT_US
74226000	SNOMEDCT_US
D010837	MESH_DESCRIPTOR_UI
D014812	MESH_DESCRIPTOR_UI
177	INN_ID
A034SE7857	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	0187-1704	TABLET	5 mg	ORAL	NDA	22 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9935	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9935	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9969	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9969	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9157	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	18 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9158	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	18 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6882	TABLET	5 mg	ORAL	ANDA	28 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	16714-973	TABLET	5 mg	ORAL	ANDA	21 sections
MEPHYTON	HUMAN PRESCRIPTION DRUG LABEL	1	21695-168	TABLET	5 mg	ORAL	NDA	21 sections
PHYTONADIONE PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
PHYTONADIONE PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Mephyton	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1753	TABLET	5 mg	ORAL	NDA	20 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4521	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	19 sections
Vitamin K1	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4523	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	19 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	50228-333	TABLET	5 mg	ORAL	ANDA	21 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	50268-661	TABLET	5 mg	ORAL	NDA authorized generic	20 sections
VITAMIN K1 - PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1536	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	13 sections
VITAMIN K1 PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1537	INJECTION, EMULSION	2 mg	INTRAMUSCULAR	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-043	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-046	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	16 sections
Phytonadione	HUMAN PRESCRIPTION DRUG LABEL	1	52584-240	INJECTION, EMULSION	1 mg	PARENTERAL	ANDA	13 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PHYTONADIONE	HUMAN PRESCRIPTION DRUG LABEL	1	52584-405	INJECTION, EMULSION	10 mg	INTRAMUSCULAR	ANDA	12 sections
PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5646	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	19 sections
PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5646	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	19 sections
Adult Infuvite Multiple Vitamins for Infusion	HUMAN PRESCRIPTION DRUG LABEL	13	54643-5649	INJECTION, SOLUTION	150 ug	INTRAVENOUS	NDA	17 sections